In the Brain of a Mouse Model of Ischemic Stroke
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Brain Death and the Cervical Spinal Cord: a Confounding Factor for the Clinical Examination
Spinal Cord (2010) 48, 2–9 & 2010 International Spinal Cord Society All rights reserved 1362-4393/10 $32.00 www.nature.com/sc REVIEW Brain death and the cervical spinal cord: a confounding factor for the clinical examination AR Joffe, N Anton and J Blackwood Department of Pediatrics, Stollery Children’s Hospital, University of Alberta, Edmonton, Alberta, Canada Study design: This study is a systematic review. Objectives: Brain death (BD) is a clinical diagnosis, made by documenting absent brainstem functions, including unresponsive coma and apnea. Cervical spinal cord dysfunction would confound clinical diagnosis of BD. Our objective was to determine whether cervical spinal cord dysfunction is common in BD. Methods: A case of BD showing cervical cord compression on magnetic resonance imaging prompted a literature review from 1965 to 2008 for any reports of cervical spinal cord injury associated with brain herniation or BD. Results: A total of 12 cases of brain herniation in meningitis occurred shortly after a lumbar puncture with acute respiratory arrest and quadriplegia. In total, nine cases of acute brain herniation from various non-meningitis causes resulted in acute quadriplegia. The cases suggest that direct compression of the cervical spinal cord, or the anterior spinal arteries during cerebellar tonsillar herniation cause ischemic injury to the cord. No case series of brain herniation specifically mentioned spinal cord injury, but many survivors had severe disability including spastic limbs. Only two pathological series of BD examined the spinal cord; 56–100% of cases had upper cervical spinal cord damage, suggesting infarction from direct compression of the cord or its arterial blood supply. -
A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated. -
Supplementary Table 1: Adhesion Genes Data Set
Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like, -
Islamic and Indian Art Including Sikh Treasures and Arts of the Punjab
Islamic and Indian Art Including Sikh Treasures and Arts of the Punjab New Bond Street, London | 23 October, 2018 Registration and Bidding Form (Attendee / Absentee / Online / Telephone Bidding) Please circle your bidding method above. Paddle number (for office use only) This sale will be conducted in accordance with 23 October 2018 Bonhams’ Conditions of Sale and bidding and buying Sale title: Sale date: at the Sale will be regulated by these Conditions. You should read the Conditions in conjunction with Sale no. Sale venue: New Bond Street the Sale Information relating to this Sale which sets out the charges payable by you on the purchases If you are not attending the sale in person, please provide details of the Lots on which you wish to bid at least 24 hours you make and other terms relating to bidding and prior to the sale. Bids will be rounded down to the nearest increment. Please refer to the Notice to Bidders in the catalogue buying at the Sale. You should ask any questions you for further information relating to Bonhams executing telephone, online or absentee bids on your behalf. Bonhams will have about the Conditions before signing this form. endeavour to execute these bids on your behalf but will not be liable for any errors or failing to execute bids. These Conditions also contain certain undertakings by bidders and buyers and limit Bonhams’ liability to General Bid Increments: bidders and buyers. £10 - 200 .....................by 10s £10,000 - 20,000 .........by 1,000s £200 - 500 ...................by 20 / 50 / 80s £20,000 -
Brain Herniation S54 (1)
BRAIN HERNIATION S54 (1) Brain Herniation Last updated: April 12, 2020 PATHOPHYSIOLOGY ................................................................................................................................. 1 TYPES OF HERNIATION ............................................................................................................................ 2 SUPRATENTORIAL MASSES .................................................................................................................... 2 Central (s. downward transtentorial) herniation ............................................................................... 2 Uncal (s. Lateral Mass) herniation ................................................................................................... 2 Cingulate (s. Subfalcine) herniation ................................................................................................. 8 INFRATENTORIAL MASSES ..................................................................................................................... 9 Cerebellar Tonsillar herniation ......................................................................................................... 9 Upward Transtentorial herniation .................................................................................................. 10 HERNIATION AFTER LUMBAR PUNCTURE ............................................................................................. 10 INVESTIGATIONS ................................................................................................................................... -
Supplementary Figures and Tables
SUPPLEMENTARY DATA Supplementary Figure 1. Isolation and culture of endothelial cells from surgical specimens of FVM. (A) Representative pre-surgical fundus photograph of a right eye exhibiting a FVM encroaching on the optic nerve (dashed line) causing tractional retinal detachment with blot hemorrhages throughout retina (arrow heads). (B) Magnetic beads (arrows) allow for separation and culturing of enriched cell populations from surgical specimens (scale bar = 100 μm). (C) Cultures of isolated cells stained positively for CD31 representing a successfully isolated enriched population (scale bar = 40 μm). ©2017 American Diabetes Association. Published online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1035/-/DC1 SUPPLEMENTARY DATA Supplementary Figure 2. Efficient siRNA knockdown of RUNX1 expression and function demonstrated by qRT-PCR, Western Blot, and scratch assay. (A) RUNX1 siRNA induced a 60% reduction of RUNX1 expression measured by qRT-PCR 48 hrs post-transfection whereas expression of RUNX2 and RUNX3, the two other mammalian RUNX orthologues, showed no significant changes, indicating specificity of our siRNA. Functional inhibition of Runx1 signaling was demonstrated by a 330% increase in insulin-like growth factor binding protein-3 (IGFBP3) RNA expression level, a known target of RUNX1 inhibition. Western blot demonstrated similar reduction in protein levels. (B) siRNA- 2’s effect on RUNX1 was validated by qRT-PCR and western blot, demonstrating a similar reduction in both RNA and protein. Scratch assay demonstrates functional inhibition of RUNX1 by siRNA-2. ns: not significant, * p < 0.05, *** p < 0.001 ©2017 American Diabetes Association. Published online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1035/-/DC1 SUPPLEMENTARY DATA Supplementary Table 1. -
Genetic Variation, Big Data and Ageing
INFRAFRONTIER / IMPC Conference 2019 Genetic Variation, Big Data and Ageing June 3 to 5, 2019 | Helsinki #InfrafrontierConf #InfraConfHelsinki WELCOME Dear colleagues, After two productive meetings in Athens (2017) and Munich (2018), the joint conference of the INFRAFRONTIER research infrastructure and the International Mouse Phenotyping Consortium (IMPC) has successfully established itself as the global platform for scientific exchange between experts from basic research to clinical research in the biomedical field – with a focus on functional phenogenomics. Martin Hrabě de Angelis This summer, we welcome you to Helsinki, the beautiful capital of INFRAFRONTIER, Finland. The aim of the INFRAFRONTIER/IMPC Conference 2019 is to Scientific Director discuss three hot topics in modern biomedical research: Genetic Variation: Understanding the functional consequences of human genetic variation and its impact on genetic diseases is critically important. This task involves systematic mutagenesis in appropriate models emulating human genetic variation, together with comprehensive genotypic and phenotypic analysis. Big Data: The availability of vast amounts of genomic and pheno typic data in the IMPC and INFRAFRONTIER databases offers the po tential to transform the biomedical research landscape. To carefully collect, analyse and interpret these huge datasets will be essential Steve Brown IMPC, Scientific Chair for the progress of genomic medicine. Ageing: In a setting of rapidly ageing societies across Europe, Ame rica, and Asia, new findings into the genetics of ageing processes and agerelated disorders uncovered using animal models are pivo tal to not only extending life but also improving its quality. We are grateful to our colleagues at the University of Oulu, together with the Finnish Ministry of Education and Culture and the Acade my of Finland, for their kind support in organizing this conference. -
Stroke Intracranial Hypertension Cerebral Edema Roman Gardlík, MD, Phd
Stroke Intracranial hypertension Cerebral edema Roman Gardlík, MD, PhD. Institute of Pathological Physiology Institute of Molecular Biomedicine [email protected] Books • Silbernagl 356 • Other book 667 Brain • The most complex structure in the body • Anatomically • Functionally • Signals to and from various part of the body are controlled by very specific areas within the brain • Brain is more vulnerable to focal lesions than other organs • Renal infarct does not have a significant effect on kidney function • Brain infarct of the same size can produce complete paralysis on one side of the body Brain • 2% of body weight • Receives 1/6 of resting cardiac output • 20% of oxygen consumption Blood-brain barrier Mechanisms of brain injury • Various causes: • trauma • tumors • stroke • metabolic dysbalance • Common pathways of injury: • Hypoxia • Ischemia • Cerebral edema • Increased intracranial pressure Hypoxia • Deprivation of oxygen with maintained blood flow • Causes: • Exposure to reduced atmospheric pressure • Carbon monoxide poisoning • Severe anemia • Failure to ogygenate blood • Well tolerated, particularly if chronic • Neurons capable of anaerobic metabolism • Euphoria, listlessness, drowsiness, impaired problem solving • Acute and severe hypoxia – unconsciousness and convulsions • Brain anoxia can result to cardiac arrest Ischemia • Reduced blood flow • Focal / global ischemia • Energy sources (glucose and glycogen) are exhausted in 2 to 4 minutes • Cellular ATP stores are depleted in 4 to 5 minutes • 50% - 75% of energy is -
Raised Intracranial Pressure Syndrome: a Stepwise Approach Swagata Tripathy1, Suma Rabab Ahmad2
NEUROCRITICAL CARE Raised Intracranial Pressure Syndrome: A Stepwise Approach Swagata Tripathy1, Suma Rabab Ahmad2 ABSTRACT Raised intracranial pressure (rICP) syndrome is seen in various pathologies. Appropriate and systematic management is important for favourable patient outcome. This review describes the stepwise approach to control the raised ICP in a tiered manner, with increasing aggressiveness. The role of ICP measurement in the assessment of cerebral autoregulation and individualised management is discussed. Although a large amount of research has been undertaken for the management of raised ICP, there still remain unanswered questions. This review tries to put together the best evidence in a succinct manner. Keywords: Complications, Cerebrospinal fluid, Hypertonic saline, Intracranial pressure, Management, Steroids Indian Journal of Critical Care Medicine (2019): 10.5005/jp-journals-10071-23190 INTRODUCTION 1,2Department of Anesthesia and Intensive Care, All India Institute of Raised intracranial pressure (rICP) syndrome is a constellation of Medical Sciences, Bhubaneswar, Odisha, India clinical symptoms and signs associated with a rise in intracranial Corresponding Author: Swagata Tripathy, Department of Anesthesia pressure. Various pathologies may lead to a rise in intracranial and Intensive Care, All India Institute of Medical Sciences, Bhubaneswar, pressure (ICP). The realm of management of raised ICP has Odisha, India, Phone: 8763400534, e-mail: tripathyswagata@gmail. progressed over time with the development of new monitoring com technology and treatment modalities. There is more clarity now How to cite this article: Tripathy S, Ahmad SR. Raised Intracranial in the understanding of the management; however, there are still Pressure Syndrome: A Stepwise Approach. Indian J Crit Care Med some gaps. Here we attempt to review the systematic approach to 2019;23(Suppl 2):S129–S135. -
Current Strategies in the Surgical Management of Ischemic Stroke
RECENT ADVANCES IN NEUROSURGERY Current Strategies in the Surgical Management of Ischemic Stroke CODY A. DOBERSTEIN, BS; RADMEHR TORABI, MD; SANDRA C. YAN, BS, BA; RYAN MCTAGGART, MD; CURTIS DOBERSTEIN, MD; MAHESH JAYARAMAN, MD ABSTRACT vessel occlusion (LVO) involving a major proximal intracra- Stroke is a major cause of death and disability in the Unit- nial artery and the efficacy of IV-tPA is significantly reduced ed States and rapid evaluation and treatment of stroke in these cases.4 Furthermore, many patients do not fit the patients are critical to good outcomes. Effective surgical strict time window and inclusion criteria for the admin- treatments aim to restore adequate cerebral blood flow, istration of IV-tPA and therefore are ineligible to receive prevent secondary brain injury, or reduce the likelihood treatment. of recurrent stroke. Patient evaluation in centers with a The recent refinement of endovascular catheter-based comprehensive stroke program and a dedicated neuro- surgical techniques, which use a stent-retriever device to vascular team is recommended. directly remove clots from occluded vessels and restore KEYWORDS: stroke, embolectomy, cerebrovascular blood flow, have proven effective in reducing morbidity occlusion and mortality in stroke patients with LVO. Several recent randomized studies have demonstrated a significant benefit of embolectomy compared to standard medical treatment alone.5,6 Due to improved outcomes, embolectomy in com- bination with IV-tPA has now become the standard of care INTRODUCTION for patients with LVO stroke. Figure 1 demonstrates pre- and Stroke is the leading cause of long-term adult disability post-angiographic images in a patient who underwent emer- in North America and the fifth leading cause of death.1,2 gent embolectomy and shows the dramatic improvement of Although some strokes are hemorrhagic, the majority (87%) cerebral perfusion following recanalization. -
A Dictionary of Neurological Signs
FM.qxd 9/28/05 11:10 PM Page i A DICTIONARY OF NEUROLOGICAL SIGNS SECOND EDITION FM.qxd 9/28/05 11:10 PM Page iii A DICTIONARY OF NEUROLOGICAL SIGNS SECOND EDITION A.J. LARNER MA, MD, MRCP(UK), DHMSA Consultant Neurologist Walton Centre for Neurology and Neurosurgery, Liverpool Honorary Lecturer in Neuroscience, University of Liverpool Society of Apothecaries’ Honorary Lecturer in the History of Medicine, University of Liverpool Liverpool, U.K. FM.qxd 9/28/05 11:10 PM Page iv A.J. Larner, MA, MD, MRCP(UK), DHMSA Walton Centre for Neurology and Neurosurgery Liverpool, UK Library of Congress Control Number: 2005927413 ISBN-10: 0-387-26214-8 ISBN-13: 978-0387-26214-7 Printed on acid-free paper. © 2006, 2001 Springer Science+Business Media, Inc. All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Springer Science+Business Media, Inc., 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dis- similar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to propri- etary rights. While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omis- sions that may be made. -
Guidelines for the Management of Severe Traumatic Brain Injury 4Th Edition
Guidelines for the Management of Severe Traumatic Brain Injury 4th Edition Nancy Carney, PhD Oregon Health & Science University, Portland, OR Annette M. Totten, PhD Oregon Health & Science University, Portland, OR Cindy O'Reilly, BS Oregon Health & Science University, Portland, OR Jamie S. Ullman, MD Hofstra North Shore-LIJ School of Medicine, Hempstead, NY Gregory W. J. Hawryluk, MD, PhD University of Utah, Salt Lake City, UT Michael J. Bell, MD University of Pittsburgh, Pittsburgh, PA Susan L. Bratton, MD University of Utah, Salt Lake City, UT Randall Chesnut, MD University of Washington, Seattle, WA Odette A. Harris, MD, MPH Stanford University, Stanford, CA Niranjan Kissoon, MD University of British Columbia, Vancouver, BC Andres M. Rubiano, MD El Bosque University, Bogota, Colombia; MEDITECH Foundation, Neiva, Colombia Lori Shutter, MD University of Pittsburgh, Pittsburgh, PA Robert C. Tasker, MBBS, MD Harvard Medical School & Boston Children’s Hospital, Boston, MA Monica S. Vavilala, MD University of Washington, Seattle, WA Jack Wilberger, MD Drexel University, Pittsburgh, PA David W. Wright, MD Emory University, Atlanta, GA Jamshid Ghajar, MD, PhD Stanford University, Stanford, CA Reviewed for evidence-based integrity and endorsed by the American Association of Neurological Surgeons and the Congress of Neurological Surgeons. September 2016 TABLE OF CONTENTS PREFACE ...................................................................................................................................... 5 ACKNOWLEDGEMENTS .............................................................................................................................................